CIBC Private Wealth Group’s Viking Therapeutics VKTX Stock Holding History

CIBC Private Wealth Group’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$17.6K	Buy	+500	New	+$17.7K	﹤0.01%	2211
2025 Q3	–	Sell	-22	Closed	-$583	–	3316
2025 Q2	$583	Sell	22 -1,339	-98%	-$35.2K	﹤0.01%	2818
2025 Q1	$27.2K	Buy	1,361 +10	+0.7%	+$316	﹤0.01%	1883
2024 Q4	$54.9K	Buy	1,351 +851	+170%	+$48.5K	﹤0.01%	1654
2024 Q3	$31.7K	Sell	500 -7	-1%	-$411	﹤0.01%	1953
2024 Q2	$25.9K	Buy	+507	New	+$33.2K	﹤0.01%	1939
2018 Q3	–	Sell	-2,000	Closed	-$19K	–	1707
2018 Q2	$19K	Buy	+2,000	New	+$13.3K	﹤0.01%	1422

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CIBC Private Wealth Group's VKTX Position: Q4 2025 in Review

CIBC Private Wealth Group opened a new position in Viking Therapeutics (VKTX) in Q4 2025: 500 shares worth $17.6K. The stake represents ﹤0.01% of the portfolio and ranks #2211 among its holdings. This is a return to the name: CIBC Private Wealth Group previously reported a position in VKTX as recently as Q2 2025.

CIBC Private Wealth Group first reported a position in VKTX in Q2 2018 and has held it in 7 quarters since. The position peaked at $54.9K in Q4 2024. 426 funds tracked by Wall St. Rank hold VKTX as of Q4 2025.

CIBC Private Wealth Group held 500 shares of Viking Therapeutics worth $17.6K as of Q4 2025.
Viking Therapeutics was a new CIBC Private Wealth Group position in Q4 2025.
Viking Therapeutics made up ﹤0.01% of CIBC Private Wealth Group's portfolio in Q4 2025, its #2211 holding.
CIBC Private Wealth Group first reported a position in Viking Therapeutics in Q2 2018 and has held it in 7 quarters since.
CIBC Private Wealth Group's Viking Therapeutics position peaked at $54.9K in Q4 2024.
426 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2025.

Based on CIBC Private Wealth Group's 13F filing for Q4 2025, filed 12 Feb 2026.